Discussion

Mechanistic synthesis

The central finding from this reanalysis is that NMN does not appear to reverse a universal transcriptional aging program across skeletal muscle, liver, and WAT. More precisely, the interaction-based analysis identified tissue-dependent patterns consistent with attenuation of selected age-associated expression changes, but it did not establish that NMN prevents transcriptional aging. The effects are largely tissue-specific. That conclusion is supported by the modest pairwise overlap among rescue lists and by the absence of any gene rescued in all three tissues. This is not a failure of the analysis. It is biologically plausible. These tissues differ in their metabolic duties, cell composition, exposure to lipid flux, endocrine function, and age-related stress. A single shared transcriptional rescue signature would have been surprising.

The stronger interpretation is that NMN may produce tissue-dependent transcriptional rescue programs that converge on related physiological outcomes (Figure 2). In skeletal muscle, the signals point toward transport, cytoskeletal organization, multivesicular body biology, and some stress-related processes, although pathway FDR support was weak. In liver, the strongest signal is suppression of fatty-acyl-CoA and long-chain fatty-acyl-CoA metabolism. In WAT, the exploratory signals involve endosome-to-Golgi transport, K63-linked ubiquitination, receptor-mediated endocytosis, Ras signaling, target of rapamycin complex 1 (TORC1) regulation, and energy precursor metabolism. These are not three copies of the same program. They look more like tissue-specific routes toward metabolic homeostasis.

Figure 2: Candidate mechanistic routes through which long-term NMN may counter age-related transcriptional driftProposed mechanistic routes by which NMN may oppose age-related transcriptional change; all panels depict hypotheses rather than measured results. (a) Rather than a single universal program, NMN engages distinct tissue-specific routes in skeletal muscle, liver, and white adipose tissue (WAT) that converge on metabolic homeostasis. (b) RAB11A, the strongest cross-tissue trafficking lead, marks recycling endosomes; its preservation could maintain receptor and membrane-cargo recycling, supporting signaling turnover and protein quality control in aged tissue. (c) CPT2, the only robust mitochondrial gene, completes the carnitine shuttle on the inner mitochondrial membrane, implicating support of long-chain fatty-acid oxidation capacity rather than broad mitochondrial biogenesis. (d) In liver, the dominant signal is suppression of fatty-acyl-CoA biosynthesis, suggesting systemic benefit through hepatic lipid remodeling and an improved plasma lipid profile. Schematics illustrate candidate mechanisms only; no quantitative findings are shown.Image created by the author using PowerPoint (Microsoft® Corp., Redmond, WA).

RAB11A is the clearest trafficking lead. Its rescue in skeletal muscle and WAT, direction consistency, high-confidence status in at least one tissue, and repeated appearance in GSEA leading-edge terms make it the strongest cross-tissue candidate in this dataset. However, repeated GSEA leading-edge membership should be viewed as a prioritization signal rather than independent functional confirmation. The biological appeal is straightforward. Aging cells must maintain the composition of the plasma membrane while managing receptor turnover, vesicle movement, organelle communication, and protein quality control. Endocytic recycling is one of the systems that supports this maintenance. If NMN helps preserve or restore RAB11A-linked recycling, it could influence how aged metabolic tissues handle signaling proteins and membrane cargo. This remains a testable hypothesis rather than a demonstrated mechanism.

CPT2 provides a second, more metabolic lead. Its rescue in both skeletal muscle and WAT fits the original report's emphasis on improved energy metabolism and skeletal-muscle oxidative function. CPT2 does not support broad mitochondrial transcriptional activation by itself. In fact, the mitochondrial enrichment results were weak and nonsignificant for the robust set. It points instead to substrate use, especially long-chain fatty-acid oxidation, as a candidate mechanism. This distinction matters. NMN may improve metabolic function not by turning on a large mitochondrial biogenesis program across tissues, but by supporting selected mitochondrial or substrate-handling components in the tissues where they matter most.

The liver result adds another layer. The strongest pathway signal was not a broad NAD+, sirtuin, or mitochondrial gene set. It was suppression of fatty-acyl-CoA biosynthetic and metabolic processes. This may help explain the improved plasma lipid profiles reported by Mills et al. [6]. If aging is accompanied by hepatic lipid remodeling, and NMN blunts part of that transcriptional program, then the liver may contribute to systemic metabolic benefit through lipid handling rather than through a simple increase in mitochondrial gene expression.

Translational implications

The translational value of this analysis lies in prioritization. RAB11A and CPT2 are not ready to serve as clinical biomarkers. They are, however, plausible pharmacodynamic candidates for validation. RAB11A could be tested as a marker of trafficking or membrane-recycling response in metabolic tissues. CPT2 could be tested as a marker of fatty-acid oxidation capacity. Both are more mechanistically specific than measuring NAD+ alone. NAD+ abundance may show exposure or pathway engagement, but it does not necessarily show which downstream tissue functions have changed.

More broadly, NAD+ repletion has been linked to mitochondrial and stem-cell phenotypes in mice, but those findings do not establish a universal transcriptional mechanism [20]. Human evidence also remains preliminary. In a small randomized, placebo-controlled trial, NMN increased muscle insulin sensitivity in postmenopausal women with prediabetes [21]. This finding provides translational context but does not establish that RAB11A or CPT2 mediates the response.

The translational hierarchy from these results is clear. The RAB11A trafficking signature has medium-term potential as a biomarker and mechanistic target, especially if future studies connect it to receptor recycling, membrane protein turnover, or insulin signaling in aged tissue. CPT2 has medium-term potential as a metabolic readout tied to fatty-acid oxidation. The liver fatty-acyl-CoA suppression signal has short- to medium-term value because it is the strongest pathway-level result and connects naturally to circulating lipid phenotypes. The broader pattern of tissue-specific rescue supports longer-term development of precision NAD+ strategies, including tissue-targeted delivery, patient stratification, and combination approaches. Direction-discordant genes, such as GALR1, add a cautionary note: a response that looks favorable in one tissue may not have the same meaning elsewhere.

These findings also help address some of the current difficulties in the NAD+ precursor field. They challenge the overly simple idea that NAD+ boosting works mainly through a single mitochondrial biogenesis pathway. They provide evidence, although still exploratory, that trafficking and substrate utilization may be important parts of the response. They also show why tissue heterogeneity should be expected rather than treated as noise. Finally, they offer a short list of genes that can be tested directly by quantitative polymerase chain reaction (qPCR), protein assays, enzyme assays, and functional experiments.

Limitations

The limitations are substantial and should be stated plainly. First, no gene reached genome-wide FDR <0.05 for the age effect, NMN at six months, or the interaction term in any tissue. All rescue lists were therefore generated using relaxed nominal thresholds. Because the nominal p <0.05 criteria were applied across thousands of probes or genes, the false-positive risk is high, particularly for candidates selected because of large coefficients or repeated nominal appearance across tissues. This makes the analysis hypothesis-generating. It does not establish definitive NMN-rescued genes.

Second, the sample size was small. Each tissue-by-age-by-treatment cell had four replicates. Interaction tests are demanding even in larger studies, and small n reduces power while increasing sensitivity to outliers. Large interaction coefficients may reflect real biology, but they may also arise from unstable variance estimates or noise, particularly for low-signal probes. A moderated linear-model sensitivity analysis was not performed, so the effect of empirical-Bayes variance moderation on the candidate lists remains unknown.

Third, the platform was an older microarray. Probe annotation, cross-hybridization, and low-confidence gene symbols can affect interpretation. The platform may also provide incomplete coverage of lowly expressed transcripts and may produce ambiguous signals for Olfr, RIK, and LOC annotations. These high-magnitude, poorly annotated genes should therefore be considered low-priority targets for experimental validation until their probe specificity is confirmed. Gene symbols, such as RAB11A and CPT2, are more interpretable, but they are still transcript-level findings from a microarray dataset.

Fourth, the mitochondrial analysis was incomplete. The run used a fallback curated mitochondrial set of 66 symbols because the full mouse MitoCarta3.0 list was not available. This means that mitochondrial enrichment may be underestimated or distorted. The nonsignificant hypergeometric P value of 0.1093 should not be interpreted as evidence that mitochondrial involvement is absent, but it also does not support broad mitochondrial restoration. The result remains provisional pending a full MitoCarta3.0 mouse reanalysis.

Fifth, GSEA results varied in strength. Liver fatty-acyl-CoA terms had the strongest FDR support. Many skeletal-muscle and WAT terms were suggestive but not statistically strong after FDR correction. Leading-edge analysis is useful for prioritizing genes such as RAB11A, but repeated leading-edge membership is not independent evidence of endocytic recycling, trafficking, or other pathway-level functional change.

Sixth, preprocessing was based on the processed GEO expression matrix. Although the values appeared to be on a compressed or log-like scale, separate density and MA-plot diagnostics were not generated as part of the original run. The absence of these diagnostics limits independent assessment of array-scale behavior and normalization adequacy.

Finally, transcription does not equal function. The analysis cannot determine whether RAB11A protein, vesicle recycling, CPT2 activity, fatty-acid oxidation flux, or insulin receptor trafficking actually changed. Those questions require targeted experiments.

Future directions

The next step should be focused validation rather than broader gene-list interpretation. RAB11A and CPT2 should be tested by qPCR in the same tissues and, ideally, in independent NMN-treated aging cohorts. Protein-level validation should follow. For RAB11A, useful assays would include endosomal recycling, receptor recycling, membrane cargo return to the cell surface, and colocalization with recycling endosome markers. If insulin sensitivity is the functional anchor, insulin receptor or glucose transporter (GLUT)-related trafficking assays would be especially relevant. For CPT2, fatty-acid oxidation assays, acylcarnitine profiling, mitochondrial respiration with lipid substrates, and CPT2 protein or activity measurements would help determine whether the transcript-level signal has metabolic consequences.

The liver fatty-acyl-CoA program should be validated with targeted lipidomics and expression assays for enzymes involved in acyl-CoA metabolism and fatty acid elongation. Because the pathway result was stronger than most individual gene results, this may be one of the most efficient validation routes. Finally, future analyses should integrate the full MitoCarta3.0 mouse gene set, updated gene annotations, ribonucleic acid sequencing (RNA-seq) datasets when available, and human NAD+ precursor studies. A future statistical sensitivity analysis using limma with empirical-Bayes moderation would also help determine whether the current candidate priorities are stable across variance-estimation frameworks. The goal should not be to prove that NMN has one universal molecular signature. The goal should be to define which tissues respond, which pathways move, and which biomarkers track functional benefit.